Crossmark

Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma

Crossref DOI link: https://doi.org/10.1186/s40425-019-0731-9

Published Online: 2019-09-18

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gupta, Swati

McCann, Leena

Chan, Yvonne G. Y.

Lai, Edwin W.

Wei, Wei

Wong, Pok Fai

Smithy, James W.

Weidler, Jodi

Rhees, Brian

Bates, Michael

Kluger, Harriet M.

Rimm, David L. https://orcid.org/0000-0001-5820-4397
Funding

Funding for this research was provided by:

Cepheid

National Cancer Institute (P30-CA016359)
License Information

Text and Data Mining valid from 2019-09-18
More Information

Article History

Received: 17 April 2019

Accepted: 4 September 2019

First Online: 18 September 2019

Ethics approval and consent to participate

: This study is approved under IRB protocol ID 9505008219.

: Not applicable

: DLR has served as a consultant/advisor to Amgen, Astra Zeneca, Agendia, Biocept, BMS, Cell Signaling Technology, Cepheid, Daiichi Sankyo, GSK, InVicro/Konica Minolta, Merck, Perkin Elmer, PAIGE.AI, and Ultivue. LM, YGYC, EWL, JW, BR and MB declare that they are employees of Cepheid. HMK has received consulting fees from Corvus, Nektar, Biodesix, Genetech, Pfizer, and Celldex, and research support from Apexigen, Merck and BMS. The remaining authors declare no competing interests.